organization · Reporting owner
Alaska Permanent Fund Corp
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Codiak BioSciences, Inc.CDAK · Entity 114958 | 10% owner | October 16, 2020 | October 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Codiak BioSciences, Inc.
Report date October 16, 2020 · Filed October 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,512,895 |
Reported balance
After 2020-10-16 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-10-16 · Conversion · Acquired 2,616,093 · Balance 4,512,895 F1: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F2: The shares are held by ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. F3: The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,512,895 |
Reported balance
After 2020-10-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-10-16 · Conversion · Acquired 467,076 · Balance 4,512,895 F1: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F4: The shares are held by Yukon Investors, LLC. The Reporting Person holds an interest in Yukon Investors, LLC. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,512,895 |
Reported balance
After 2020-10-16 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-10-16 · Conversion · Acquired 747,321 · Balance 4,512,895 F1: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F2: The shares are held by ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. F3: The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,512,895 |
Reported balance
After 2020-10-16 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2020-10-16 · Conversion · Acquired 191,721 · Balance 4,512,895 F1: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F4: The shares are held by Yukon Investors, LLC. The Reporting Person holds an interest in Yukon Investors, LLC. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,512,895 |
Reported balance
After 2020-10-16 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2020-10-16 · Conversion · Acquired 191,721 · Balance 4,512,895 F1: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F3: The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. F5: The shares are held by ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in ARCH Venture Fund VIII Overage, L.P.. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,512,895 |
Reported balance
After 2020-10-16 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2020-10-16 · Purchase · Acquired 235,000 · Balance 4,512,895 F3: The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. F6: The shares are held by ARCH Venture Fund VIII, L.P.. The Reporting Person holds an indirect interest in ARCH Venture Fund VIII, L.P.. |
| Series A redeemable convertible preferred stockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2020-10-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-10-16 · Conversion · Disposed 20,450,000 · Balance 0 F1: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F7: Each share of Series A Preferred Stock converted automatically into Common Stock on a 1-for-7.8170 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the issuer's initial public offering on October 16, 2020. F2: The shares are held by ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. F3: The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. |
| Series B redeemable convertible preferred stockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2020-10-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-10-16 · Conversion · Disposed 3,333,333 · Balance 0 F1: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F8: Each share of Series B Preferred Stock converted automatically into Common Stock on a 1-for-7.1366 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series B Preferred Stock was convertible based on a 1-for-7.1295 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. F4: The shares are held by Yukon Investors, LLC. The Reporting Person holds an interest in Yukon Investors, LLC. |
| Series B redeemable convertible preferred stockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2020-10-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-10-16 · Conversion · Disposed 5,333,333 · Balance 0 F1: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F8: Each share of Series B Preferred Stock converted automatically into Common Stock on a 1-for-7.1366 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series B Preferred Stock was convertible based on a 1-for-7.1295 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. F2: The shares are held by ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. F3: The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. |
| Series C redeemable convertible preferred stockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2020-10-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-10-16 · Conversion · Disposed 1,320,097 · Balance 0 F1: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F9: Each share of Series C Preferred Stock converted automatically into Common Stock on a 1-for-6.8855 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the Issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. F4: The shares are held by Yukon Investors, LLC. The Reporting Person holds an interest in Yukon Investors, LLC. |
| Series C redeemable convertible preferred stockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2020-10-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-10-16 · Conversion · Disposed 1,320,097 · Balance 0 F1: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F9: Each share of Series C Preferred Stock converted automatically into Common Stock on a 1-for-6.8855 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the Issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. F3: The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. F5: The shares are held by ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in ARCH Venture Fund VIII Overage, L.P.. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock.
F2: The shares are held by ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P..
F3: The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose.
F4: The shares are held by Yukon Investors, LLC. The Reporting Person holds an interest in Yukon Investors, LLC.
F5: The shares are held by ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in ARCH Venture Fund VIII Overage, L.P..
F6: The shares are held by ARCH Venture Fund VIII, L.P.. The Reporting Person holds an indirect interest in ARCH Venture Fund VIII, L.P..
F7: Each share of Series A Preferred Stock converted automatically into Common Stock on a 1-for-7.8170 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the issuer's initial public offering on October 16, 2020.
F8: Each share of Series B Preferred Stock converted automatically into Common Stock on a 1-for-7.1366 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series B Preferred Stock was convertible based on a 1-for-7.1295 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering.
F9: Each share of Series C Preferred Stock converted automatically into Common Stock on a 1-for-6.8855 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the Issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Vir Biotechnology, Inc.
Report date October 16, 2019 · Filed October 16, 2019
Section 16 reporting ended · disclosed 2019-10-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Yukon Investors, LLC | 5,555,556 |
Reported balance
After 2019-10-16 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-10-16 · Conversion · Acquired 2,222,222 · Balance 5,555,556 F1: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. |
| Common StockSEC Table I · non-derivative | IndirectBy Yukon Investors, LLC | 5,555,556 |
Reported balance
After 2019-10-16 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-10-16 · Conversion · Acquired 1,111,111 · Balance 5,555,556 F1: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. |
| Common StockSEC Table I · non-derivative | IndirectBy Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P | 5,555,556 |
Reported balance
After 2019-10-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-10-16 · Conversion · Acquired 666,667 · Balance 5,555,556 F1: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. |
| Common StockSEC Table I · non-derivative | IndirectBy Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P | 5,555,556 |
Reported balance
After 2019-10-16 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2019-10-16 · Conversion · Acquired 55,556 · Balance 5,555,556 F1: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. |
| Common StockSEC Table I · non-derivative | Direct | 5,555,556 |
Reported balance
After 2019-10-16 transaction · row 5
1 source rowRow 5 · 2019-10-16 · Purchase · Acquired 1,500,000 · Balance 5,555,556 |
| Series A-1 convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Yukon Investors, LLC | 0 |
Reported balance
After 2019-10-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-10-16 · Conversion · Disposed 2,222,222 · Balance 0 F1: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. |
| Series A-1 convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P | 0 |
Reported balance
After 2019-10-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-10-16 · Conversion · Disposed 666,667 · Balance 0 F1: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Yukon Investors, LLC | 0 |
Reported balance
After 2019-01-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-01-16 · Conversion · Disposed 1,111,111 · Balance 0 F1: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P | 0 |
Reported balance
After 2019-10-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-10-16 · Conversion · Disposed 55,556 · Balance 0 F1: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 16, 2020 Filed Oct 23, 2020 18:38 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | ConversionSeries C redeemable convertible preferred stock · Derivative | 1,320,097 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-20-000826 · form4.xml · derivative · entry 11 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 191,721 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F1 · derivative.exercise_date: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F1 · derivative.expiration_date: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F9 · derivative.underlying_shares: Each share of Series C Preferred Stock converted automatically into Common Stock on a 1-for-6.8855 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the Issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. F5 · ownership.nature: The shares are held by ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in ARCH Venture Fund VIII Overage, L.P.. Read SEC document |
| October 16, 2020 Filed Oct 23, 2020 18:38 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | ConversionSeries C redeemable convertible preferred stock · Derivative | 1,320,097 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-20-000826 · form4.xml · derivative · entry 10 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 191,721 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F1 · derivative.exercise_date: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F1 · derivative.expiration_date: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F9 · derivative.underlying_shares: Each share of Series C Preferred Stock converted automatically into Common Stock on a 1-for-6.8855 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the Issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. F4 · ownership.nature: The shares are held by Yukon Investors, LLC. The Reporting Person holds an interest in Yukon Investors, LLC. Read SEC document |
| October 16, 2020 Filed Oct 23, 2020 18:38 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | ConversionSeries B redeemable convertible preferred stock · Derivative | 5,333,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-20-000826 · form4.xml · derivative · entry 9 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 747,321 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F1 · derivative.exercise_date: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F1 · derivative.expiration_date: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F8 · derivative.underlying_shares: Each share of Series B Preferred Stock converted automatically into Common Stock on a 1-for-7.1366 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series B Preferred Stock was convertible based on a 1-for-7.1295 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. F2 · ownership.nature: The shares are held by ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. Read SEC document |
| October 16, 2020 Filed Oct 23, 2020 18:38 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | ConversionSeries B redeemable convertible preferred stock · Derivative | 3,333,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-20-000826 · form4.xml · derivative · entry 8 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 467,076 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F1 · derivative.exercise_date: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F1 · derivative.expiration_date: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F8 · derivative.underlying_shares: Each share of Series B Preferred Stock converted automatically into Common Stock on a 1-for-7.1366 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series B Preferred Stock was convertible based on a 1-for-7.1295 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. F4 · ownership.nature: The shares are held by Yukon Investors, LLC. The Reporting Person holds an interest in Yukon Investors, LLC. Read SEC document |
| October 16, 2020 Filed Oct 23, 2020 18:38 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | ConversionSeries A redeemable convertible preferred stock · Derivative | 20,450,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-20-000826 · form4.xml · derivative · entry 7 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,616,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F1 · derivative.exercise_date: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F1 · derivative.expiration_date: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F7 · derivative.underlying_shares: Each share of Series A Preferred Stock converted automatically into Common Stock on a 1-for-7.8170 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the issuer's initial public offering on October 16, 2020. F2 · ownership.nature: The shares are held by ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. Read SEC document |
| October 16, 2020 Filed Oct 23, 2020 18:38 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | PurchaseCommon Stock | 235,000 | $15.00 | $3,525,000.00 |
DisclosureSEC source: 0000898432-20-000826 · form4.xml · nonDerivative · entry 6 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,512,895 F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. F6 · ownership.nature: The shares are held by ARCH Venture Fund VIII, L.P.. The Reporting Person holds an indirect interest in ARCH Venture Fund VIII, L.P.. Read SEC document |
| October 16, 2020 Filed Oct 23, 2020 18:38 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | ConversionCommon Stock | 191,721 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-20-000826 · form4.xml · nonDerivative · entry 5 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,512,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. F5 · ownership.nature: The shares are held by ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in ARCH Venture Fund VIII Overage, L.P.. Read SEC document |
| October 16, 2020 Filed Oct 23, 2020 18:38 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | ConversionCommon Stock | 191,721 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-20-000826 · form4.xml · nonDerivative · entry 4 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,512,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F4 · ownership.nature: The shares are held by Yukon Investors, LLC. The Reporting Person holds an interest in Yukon Investors, LLC. Read SEC document |
| October 16, 2020 Filed Oct 23, 2020 18:38 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | ConversionCommon Stock | 747,321 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-20-000826 · form4.xml · nonDerivative · entry 3 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,512,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F2 · ownership.nature: The shares are held by ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. Read SEC document |
| October 16, 2020 Filed Oct 23, 2020 18:38 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | ConversionCommon Stock | 467,076 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-20-000826 · form4.xml · nonDerivative · entry 2 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,512,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F4 · ownership.nature: The shares are held by Yukon Investors, LLC. The Reporting Person holds an interest in Yukon Investors, LLC. Read SEC document |
| October 16, 2020 Filed Oct 23, 2020 18:38 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | ConversionCommon Stock | 2,616,093 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-20-000826 · form4.xml · nonDerivative · entry 1 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,512,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. F2 · ownership.nature: The shares are held by ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. Read SEC document |
| October 16, 2019 Filed Oct 16, 2019 20:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries B convertible preferred stock · Derivative | 55,556 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001253 · form4.xml · derivative · entry 9 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P Disclosed balance after: 0 Underlying: Common Stock · 55,556 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. F1 · derivative.exercise_date: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. F1 · derivative.expiration_date: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. Read SEC document |
| October 16, 2019 Filed Oct 16, 2019 20:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries A-1 convertible preferred stock · Derivative | 666,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001253 · form4.xml · derivative · entry 7 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P Disclosed balance after: 0 Underlying: Common Stock · 666,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. F1 · derivative.exercise_date: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. F1 · derivative.expiration_date: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. Read SEC document |
| October 16, 2019 Filed Oct 16, 2019 20:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries A-1 convertible preferred stock · Derivative | 2,222,222 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001253 · form4.xml · derivative · entry 6 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Yukon Investors, LLC Disclosed balance after: 0 Underlying: Common Stock · 2,222,222 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. F1 · derivative.exercise_date: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. F1 · derivative.expiration_date: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. Read SEC document |
| October 16, 2019 Filed Oct 16, 2019 20:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | PurchaseCommon Stock | 1,500,000 | $20.00 | $30,000,000.00 |
DisclosureSEC source: 0000898432-19-001253 · form4.xml · nonDerivative · entry 5 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,555,556 Read SEC document |
| October 16, 2019 Filed Oct 16, 2019 20:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 55,556 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-001253 · form4.xml · nonDerivative · entry 4 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P Disclosed balance after: 5,555,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. Read SEC document |
| October 16, 2019 Filed Oct 16, 2019 20:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 1,111,111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-001253 · form4.xml · nonDerivative · entry 3 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Yukon Investors, LLC Disclosed balance after: 5,555,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. Read SEC document |
| October 16, 2019 Filed Oct 16, 2019 20:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 666,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-001253 · form4.xml · nonDerivative · entry 2 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P Disclosed balance after: 5,555,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. Read SEC document |
| October 16, 2019 Filed Oct 16, 2019 20:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 2,222,222 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-001253 · form4.xml · nonDerivative · entry 1 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Yukon Investors, LLC Disclosed balance after: 5,555,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. Read SEC document |
| January 16, 2019 Filed Oct 16, 2019 20:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries B convertible preferred stock · Derivative | 1,111,111 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001253 · form4.xml · derivative · entry 8 Alaska Permanent Fund Corp · CIK 0001582681 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Yukon Investors, LLC Disclosed balance after: 0 Underlying: Common Stock · 1,111,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. F1 · derivative.exercise_date: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. F1 · derivative.expiration_date: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.